FOR PSORIASIS PATIENTS (SEE ALSO BOXED WARNINGS ABOVE)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Neoral®.
Cyclosporine, the active ingredient in Neoral®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.
|
| |
NEORAL SUMMARY
Neoral
Neoral® is an oral formulation of cyclosporine that immediately forms a microemulsion in an aqueous environment.
Neoral® is indicated for the following:
Kidney, Liver, and Heart Transplantation: Neoral® is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Neoral® has been used in combination with azathioprine and corticosteroids.
Rheumatoid Arthritis: Neoral® is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Neoral® can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone.
Psoriasis: Neoral® is indicated for the treatment of
adult, nonimmunocompromised
patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated.
While rebound rarely occurs, most patients will experience relapse with Neoral® as with other therapies upon cessation of treatment.
|
NEWS HIGHLIGHTS
Published Studies Related to Neoral (Cyclosporine)
Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. [2009.09.22]
BACKGROUND: Early and long-term use of cyclosporine A (CsA) leads to increased risks of renal toxicity. We hypothesized that administration of daclizumab in combination with mycophenolate mofetil (MMF) allows a relevant reduction in the dose of CsA... CONCLUSION: We demonstrate here that high-dose daclizumab in combination with lower CsA levels in adult renal transplant recipients is as or more effective than standard regimen (CsA, MMF, steroids) and may result in better outcomes at 12 months post-transplant with no increase in adverse reactions.
Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. [2009.07.27]
BACKGROUND: Real-time contrast enhanced sonography (CES) provides quantitative information on microvascular tissue perfusion in renal allografts. In contrast to calcineurin inhibitors, mammalian target of rapamycin inhibitors may have beneficial effects on renal microvascular tissue perfusion. There is no information on the microperfusion of renal allografts in patients receiving either mammalian target of rapamycin inhibitor or calcineurin inhibitor... CONCLUSION: The study demonstrates that renal microperfusion visualized by CES based on microbubble contrast agent and concomitantly kidney function, improved significantly after the switch from CsA to EVR.
Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. [2009.07.15]
BACKGROUND: Pharmacokinetic modeling supports trough monitoring of everolimus, but prospective data comparing this approach versus mycophenolate mofetil (MMF) in de novo cardiac transplant recipients are currently unavailable... CONCLUSION: Concentration-controlled everolimus with reduced CsA results in similar renal function and equivalent efficacy compared with MMF with standard CsA at 12 months after cardiac transplantation.
Inhaled Cyclosporine and Pulmonary Function in Lung Transplant Recipients. [2009.07.06]
Abstract Background: Chronic rejection, manifesting as bronchiolitis obliterans, is the leading cause of death in lung transplant recipients.
Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. [2009.07]
Renal transplant recipients show an increased risk of cardiovascular disease compared with a nontransplant population. Herein we have shown an analysis of a randomized controlled trial wherein 525 patients receiving a first or second (9.7%) renal allograft from a deceased (89.1%), a living-related (7.8%), or a living-unrelated donor (3.1%) received sirolimus (SRL), cyclosporine (CsA), and steroids (ST) at the time of transplantation with randomization at 3 months after transplantation of 430 eligible patients to continue on SRL-CsA-ST or to have CsA withdrawn with increased SRL trough targets (SRL-ST group)...
Clinical Trials Related to Neoral (Cyclosporine)
Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation [Completed]
We have previously defined factors that predict the long term success of maintenance CsA
monotherapy (CsAm) after kidney transplantation : donor age < 40 years, serum creatinine
level at the initiation of CsAm £ 125 µmol/L, no rejection episode before CsAm initiation. We
have also shown that the 8-year graft survival in 329 selected patients enrolled in
maintenance CsA-m was 84 % (Hurault de Ligny et al, Transplantation, 2000 ; 69 : 1327-1332).
These results were obtained with an old formulation of cyclosporin, azathioprine, steroid
withdrawal over the first year and induction antibody. This prospective randomized
multicentre study was designed to clarify whether maintenance Neoral + MMF or Neoral + AZA is
better than a CsAm and wether Neoral + MMF is better than Neoral + AZA in low immunological
risk cadaveric kidney transplant recipients.
Metabolic Pattern of Cyclosporine A and Acute Renal Failure [Completed]
Following heart transplantation many patients develop acute renal failure in the early
posttransplant phase and some are in need of renal replacement therapy for shorter or longer
time. The cause of this acute renal failure is most probably multi factorial but many reports
indicate that cyclosporine has a central role in the pathophysiology and it is generally
recommended to lower the cyclosporine load to patients developing acute renal failure in this
population.
Several in vitro studies on renal cells in culture indicate that the primary metabolites of
cyclosporine (AM1, AM9, AM4N) are less toxic to the kidney than cyclosporine itself. However,
the secondary metabolite AM19 as well as the cyclic metabolites AM1c and AM1c9 has been
associated with decreased renal function and nephrotoxicity renal transplant recipients.
The primary objective of this pilot study is to investigate if the concentrations of
secondary- and cyclic metabolites of cyclosporine (AM19, AM1c, AM1c9) is related to
development of acute renal failure in the early posttransplant phase following heart
transplantation.
Secondary objectives are to investigate associations between genotypes of P-glycoprotein and
CYP3A5 and the metabolic pattern of cyclosporine.
Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? [Completed]
The purpose of this study is to determine whether reducing inflammation of the surface of the
eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase
patient comfort.
Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels [Active, not recruiting]
The main purpose of this study is to identify cyclosporine C2 levels during 12 months
treatment , while cyclosporine microemulsion dosages are adjusted based on C0 cyclosporine
blood samples, and retrospectively correlate C2 levels to outcome (renal function and
incidence of acute rejections)
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients [Active, not recruiting]
|
|
|
|
Page last updated: 2009-10-20
|
